Zurich Cantonal Bank
CLDX icon

Zurich Cantonal Bank’s Celldex Therapeutics CLDX Stock Holding History

Zurich Cantonal Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,317
Closed -$688K – 2766
2025
Q4 		$688K Buy
+25,317
New +$667K ﹤0.01% 1577

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zurich Cantonal Bank's CLDX Position: Q2 2026 in Review

Zurich Cantonal Bank held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 30,677 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1472.

Zurich Cantonal Bank first reported a position in CLDX in Q2 2014 and has held it in 35 quarters since. The position peaked at $4.04M in Q4 2015. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Zurich Cantonal Bank held 30,677 shares of Celldex Therapeutics worth $1.14M as of Q2 2026.
  • Zurich Cantonal Bank left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1472 holding.
  • Zurich Cantonal Bank first reported a position in Celldex Therapeutics in Q2 2014 and has held it in 35 quarters since.
  • Zurich Cantonal Bank's Celldex Therapeutics position peaked at $4.04M in Q4 2015.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.